Tazarotene and Mometasone furoate is in fixed dose combination (Cream), used in plaque psoriasis. A simple, precise, rapid, accurate and specific RP-HPLC method have been developed and validated to determine Tazarotene (TAZA) and Mometasone Furoate (MOMETAS), in cream formulation. The RP-HPLC method was developed and validated for simultaneous estimation of Tazarotene and Mometasone furoate in its formulation using Lichrosphere C18 column (250 X 4.6mm, 5 �µm) as stationary phase and Methanol: Water in the proportion of 90:10, v/v and the pH of mobile phase was adjusted to 3.8 using 0.5% v/v Orthophosphoric acid. The detection was carried out at 248 nm using UV detector keeping the flow rate of 1.0 ml/min and injection volume 20 �µl. Retention time of Tazarotene and Mometasone furoate was found to be 8.31 and 3.51 min, respectively. Linearity was found over the concentration range of 1-5 �µg/ml for TAZA (R2 = 0.9992) and 1-5 �µg/ml for MOMETAS (R2 = 0.9994) with mean recoveries of 98.00-100.67% for TAZA and 99.00-100.11% MOMETAS, respectively. The LOD was found to be 0.0155 �µg mL-1 for TAZA and 0.0103 �µg mL-1 for MOMETAS. The LOQ was found to be 0.0469 �µg mL-1 for TAZA and 0.0307 �µg mL-1 for MOMETAS. The assay percentage was comparable with the label claim percentage for both TAZA and MOMETAS. The method was validated as per ICH guidelines Q2 (R1).The method was successfully applied for the determination of TAZA and MOMETAS in their cream formulation.
Loading....